A zebrafish model of intrahepatic cholangiocarcinoma by dual expression of hepatitis B virus X and hepatitis C virus core protein in liver

Wangta Liu, Jim‐Ray Chen, Chih‐Hao Hsu, Yen‐Hsing Li, Yi‐Meng Chen, Chien‐Yuan Lin, Shin‐Jie Huang, Zen‐Kuei Chang, Yen‐Chun Chen, Chi‐Hsueh Lin, Hong‐Yi Gong, Ching‐Chun Lin, Koichi Kawakami, Jen‐Leih Wu – 22 June 2012 – The mechanisms that mediate the initiation and development of intrahepatic cholangiocarcinoma (ICC) associated with hepatitis B and C virus (HBV and HCV, respectively) infection remain largely unclear.

Clinical outcomes of patients with hepatorenal syndrome after living donor liver transplantation

Jung Pyo Lee, Hyuk Yong Kwon, Ji In Park, Nam‐Joon Yi, Kyung‐Suk Suh, Hae Won Lee, Myounghee Kim, Yun Kyu Oh, Chun Soo Lim, Yon Su Kim – 19 June 2012 – Liver transplantation (LT) is the treatment of choice for hepatorenal syndrome (HRS). However, the clinical benefits of living donor liver transplantation (LDLT) are not yet well established. We, therefore, investigated the outcomes of patients with HRS who underwent LDLT and patients with HRS who received transplants from deceased donors.

Jaundice increases the rate of complications and one‐year mortality in patients with hypoxic hepatitis

Bernhard Jäger, Andreas Drolz, Barbara Michl, Peter Schellongowski, Andja Bojic, Miriam Nikfardjam, Christian Zauner, Gottfried Heinz, Michael Trauner, Valentin Fuhrmann – 18 June 2012 – Hypoxic hepatitis (HH) is the most frequent cause of acute liver injury in critically ill patients. No clinical data exist about new onset of jaundice in patients with HH. This study aimed to evaluate the incidence and clinical effect of jaundice in critically ill patients with HH. Two hundred and six consecutive patients with HH were screened for the development of jaundice during the course of HH.

Liver specific inactivation of carboxylesterase 3/triacylglycerol hydrolase decreases blood lipids without causing severe steatosis in mice

Jihong Lian, Enhui Wei, Shu Pei Wang, Ariel D. Quiroga, Lena Li, Alba Di Pardo, Jelske van der Veen, Simonetta Sipione, Grant A. Mitchell, Richard Lehner – 18 June 2012 – Carboxylesterase 3/triacylglycerol hydrolase (Ces3/TGH) participates in hepatic very low‐density lipoprotein (VLDL) assembly and in adipose tissue basal lipolysis. Global ablation of Ces3/Tgh expression decreases serum triacylglycerol (TG) and nonesterified fatty acid levels and improves insulin sensitivity.

Recommendations for standardized nomenclature and definitions of viral response in trials of hepatitis C virus investigational agents

Heiner Wedemeyer, Donald M. Jensen, Eliot Godofsky, Nina Mani, Jean‐Michel Pawlotsky, Veronica Miller, on behalf of the Definitions/Nomenclature Working Group* of the HCV DrAG (HCV Drug Development Advisory Group), under the auspices of the Forum for Collaborative HIV Research – 18 June 2012 – Outdated virological response terms used at key trial timepoints in clinical trials with first‐generation direct‐acting antivirals plus pegylated interferon and ribavirin have failed to keep pace with hepatitis C virus (HCV) drug development.

Subscribe to